24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Richard Francis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
15:00
Cyber unicorn Semperis acquires MightyID in $20 million identity security deal
14:42
Cyera employees to sell tens of millions in shares at $9 billion valuation
11:14
“The revolutionary AI social network is largely humans operating fleets of bots”
10:27
“Israeli tech post-October 7th could not be in a better position”
More stories
Buzz
Most popular
Daily
Weekly
1
Chinese fund: “The Chinese government has imposed a ban on any new investment in Israel”
2
Israeli defense firms target Asia as Singapore Airshow opens amid regional arms race
3
Medtronic to acquire Israeli AI cardiology firm CathWorks for $585 million, deal could reach $1 billion
4
After $400M cyber exit, ex-IntSights CEO raises $11M to build AI app for personalized sports highlights
5
“SaaS is dying as a business category”
More news
Richard Francis
4 stories about Richard Francis
After a threefold rally, Teva faces its next test
29.01.26
|
Sophie Shulman
Innovative drugs surge, but 2026 forecasts revive investor doubts.
Teva surpasses expectations in Q4 but sets cautious outlook for 2025
29.01.25
|
Sophie Shulman
Despite a strong finish to the year, Teva forecasts lower-than-expected earnings and revenue growth for 2025.
Teva soars with double-digit growth in Q3, raises annual forecast
06.11.24
|
Sophie Shulman
Strong sales of Austedo and Ajovy push Teva’s revenues above expectations, with the company forecasting up to $16.5 billion in 2024.
Teva CEO: "The company played not to lose, now we’ll play to win"
21.02.24
|
Sophie Shulman
Richard Francis' decision to focus on innovative drugs has boosted the stock by 40% since he took office. However, the high debt is still burdensome and the realization of the potential depends on the success of developments that are still in the laboratory